SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RCMac who wrote (2786)5/17/1999 7:04:00 AM
From: BMcV  Read Replies (1) of 10280
 
Nori trial date link: sepracor.com

Here's a summary:

>> More than 3,300 patients with perennial and/or seasonal allergic rhinitis have received norastemizole in clinical trials Norastemizole at a dose of 30 mg demonstrates an effect on symptoms of allergic rhinitis within 20 minutes after dosing Norastemizole at a dose of 30 mg reduces symptoms for up to 24 hours in subjects with seasonal allergic rhinitis Norastemizole at 30 mg was well-tolerated, with no reports of weight gain in clinical studies and no obvious sedation <<

Due to formatting reasons, I can't publish more here, but at first blush results look very good to me, much better than I expected. Nori is 30 times more potent at binding H1 receptors than loratadine, and ten times better than the parent compound, astemizole. Side effects look about comparable with placebo, and onset of activity is about 20 minutes, which has been a big problem with Hismanal. Activity lasts 24 hours. J&J simply made a business decision, not a judgement on this drug.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News